In another in vitro study on glioblastoma by Morimoto and colleagues, the knockout of TIM-3 with the use of CRISPR/Cas9 technology was shown to be beneficial in increasing inhibition of glioblastoma tumor cell growth without interfering with the expression of other NK cell inhibitory receptors [142]. The gene discussed is HAVCR2; the disease is glioblastoma.